Overview

Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Arbekacin for the use of infection caused by multidrug-resistant organisms
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command
U.S. Army Medical Research and Materiel Command
Collaborators:
Meiji Seika Pharma Co., Ltd.
Uniformed Services University of the Health Sciences
Treatments:
Arbekacin
Dibekacin
Habekacin